单克隆抗体在新型冠状病毒感染Covid-19中的临床和免疫学应用

S. Bazarova, Z. Saatov, M. Nazirova
{"title":"单克隆抗体在新型冠状病毒感染Covid-19中的临床和免疫学应用","authors":"S. Bazarova, Z. Saatov, M. Nazirova","doi":"10.48112/acmr.v3i4.43","DOIUrl":null,"url":null,"abstract":"To date, methods of prevention and treatment of coronavirus infections have not been developed in essence. One of the reasons for this situation may be the peculiarities of the pathogenesis of coronavirus infection and the rapid development of the pandemic, which could hinder the effectiveness of ongoing research. As with any viral infection, with the development and spread of the inflammatory process, viremia develops, that is, the generalization of infection, cytokine secretion becomes uncontrolled, and the concentration of IFNy, IL-1, IL-6, IL-12 in the blood serum significantly increases, in other words, the primary inflammatory reaction enters a new phase — the cytokine storm phase, which manifests itself violently even according to clinical and laboratory parameters. In this regard, adequate therapy aimed at stopping the uncontrolled process induced not so much by viremia as by the associated inflammation is crucial. In this regard, the aim of our study was to study the effect of monoclonal antibodies, in particular the drug \"Kazirivimab + Imdevimab\"— a combination of recombinant monoclonal antibodies directed against S-protein on the clinical course and laboratory data in patients with a new coronavirus infection –Covid-19.","PeriodicalId":7266,"journal":{"name":"Advances in Clinical Medical Research and Healthcare Delivery","volume":"61 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical and Immunological Aspects of the Use of Monoclonal Antibodies in the New Coronavirus Infection Covid-19\",\"authors\":\"S. Bazarova, Z. Saatov, M. Nazirova\",\"doi\":\"10.48112/acmr.v3i4.43\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To date, methods of prevention and treatment of coronavirus infections have not been developed in essence. One of the reasons for this situation may be the peculiarities of the pathogenesis of coronavirus infection and the rapid development of the pandemic, which could hinder the effectiveness of ongoing research. As with any viral infection, with the development and spread of the inflammatory process, viremia develops, that is, the generalization of infection, cytokine secretion becomes uncontrolled, and the concentration of IFNy, IL-1, IL-6, IL-12 in the blood serum significantly increases, in other words, the primary inflammatory reaction enters a new phase — the cytokine storm phase, which manifests itself violently even according to clinical and laboratory parameters. In this regard, adequate therapy aimed at stopping the uncontrolled process induced not so much by viremia as by the associated inflammation is crucial. In this regard, the aim of our study was to study the effect of monoclonal antibodies, in particular the drug \\\"Kazirivimab + Imdevimab\\\"— a combination of recombinant monoclonal antibodies directed against S-protein on the clinical course and laboratory data in patients with a new coronavirus infection –Covid-19.\",\"PeriodicalId\":7266,\"journal\":{\"name\":\"Advances in Clinical Medical Research and Healthcare Delivery\",\"volume\":\"61 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Clinical Medical Research and Healthcare Delivery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.48112/acmr.v3i4.43\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical Medical Research and Healthcare Delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48112/acmr.v3i4.43","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

迄今为止,冠状病毒感染的预防和治疗方法尚未从本质上发展起来。造成这种情况的原因之一可能是冠状病毒感染发病机制的特殊性和大流行的快速发展,这可能会阻碍正在进行的研究的有效性。与任何病毒感染一样,随着炎症过程的发展和扩散,病毒血症发生,即感染的普遍化,细胞因子分泌失控,血清中IFNy、IL-1、IL-6、IL-12的浓度显著升高,即原发性炎症反应进入了一个新的阶段——细胞因子风暴期,即使从临床和实验室参数来看,该阶段的表现也很剧烈。在这方面,适当的治疗旨在阻止不受控制的过程,而不是由病毒血症引起的,而是由相关的炎症引起的,这是至关重要的。因此,我们的研究目的是研究单克隆抗体,特别是针对s蛋白的重组单克隆抗体组合“Kazirivimab + Imdevimab”对新型冠状病毒感染- covid -19患者临床病程和实验室数据的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical and Immunological Aspects of the Use of Monoclonal Antibodies in the New Coronavirus Infection Covid-19
To date, methods of prevention and treatment of coronavirus infections have not been developed in essence. One of the reasons for this situation may be the peculiarities of the pathogenesis of coronavirus infection and the rapid development of the pandemic, which could hinder the effectiveness of ongoing research. As with any viral infection, with the development and spread of the inflammatory process, viremia develops, that is, the generalization of infection, cytokine secretion becomes uncontrolled, and the concentration of IFNy, IL-1, IL-6, IL-12 in the blood serum significantly increases, in other words, the primary inflammatory reaction enters a new phase — the cytokine storm phase, which manifests itself violently even according to clinical and laboratory parameters. In this regard, adequate therapy aimed at stopping the uncontrolled process induced not so much by viremia as by the associated inflammation is crucial. In this regard, the aim of our study was to study the effect of monoclonal antibodies, in particular the drug "Kazirivimab + Imdevimab"— a combination of recombinant monoclonal antibodies directed against S-protein on the clinical course and laboratory data in patients with a new coronavirus infection –Covid-19.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信